GLP‑1 Receptor Agonists and Limb Outcomes: What a 645,000‑Patient Study Tells Us
A nationwide retrospective cohort analysis published this week in Diabetes Care explores whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) confer advantages over sodium–glucose cotransporter‑2 inhibitors (SGLT2i) for lower‑extremity events in type 2 diabetes. Led by Dr Tze‑Woei Tan, the investigation examined 645,121 individuals newly started on either drug class between May 2013 and March 2025. After 1:1 propensity‑score matching, each treatment arm contained 180,740 people who were followed for up to three years.
Key Findings
| Outcome | GLP‑1 RA vs SGLT2i | Hazard Ratio (95 % CI) | Interpretation |
|---|---|---|---|
| Above‑ankle amputation‑free survival | 99.69 % vs 99.64 % | — | Small but statistically significant absolute difference |
| Above‑ankle amputation | — | 0.77 (0.66–0.90) | 23 % relative risk reduction |
| Diabetic foot ulcer | — | 0.92 (0.87–0.96) | 8 % relative risk reduction |
| All‑cause mortality | — | 0.66 (0.63–0.69) | 34 % relative risk reduction |
Why This Matters
Lower‑extremity ulceration and amputation remain devastating complications, even as cardiometabolic therapies evolve. Although SGLT2 inhibitors have reshaped cardiovascular and renal care, their class warnings about amputation risk created lingering concern. This real‑world analysis suggests that GLP‑1 RAs may offer a modest but meaningful protective association—not only against major limb loss but also against foot ulceration and overall mortality.
Strengths and Caveats
- Scale and representativeness: The cohort spans more than a decade of routine practice, enhancing external validity.
- Rigorous matching: Detailed propensity balancing helps address measured confounding.
- Observational design: Residual and unmeasured confounding cannot be excluded; causal inference should be cautious.
- Drug heterogeneity: Individual agents within each drug class were not compared head‑to‑head.
- Follow‑up horizon: Three years may underestimate very long‑term limb outcomes.
Clinical Take‑Home
For clinicians weighing second‑line glucose‑lowering therapies in patients at risk for foot complications, these findings support GLP‑1 RAs as a potentially advantageous option. Prospective, mechanistic, and randomized studies will be important next steps, but the present data contribute to an emerging narrative: medication choice in diabetes management may influence not only glycaemia and cardiovascular endpoints but also limb preservation and survival.
Full Author Line‑up
Hong AT, Luu IY, Lin F, Shin L, Hsu C‑H, Shih C‑D, Armstrong DG, Tan T‑W (corresponding author).
Citation & Link
Hong AT, Luu IY, Lin F, Shin L, Hsu C‑H, Shih C‑D, Armstrong DG, Tan T‑W. “Differential Effect of GLP‑1 Receptor Agonists and SGLT2 Inhibitors on Lower‑Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study.” Diabetes Care. Online ahead of print 25 June 2025. doi: 10.2337/dc25‑0292.
Leave a Reply